- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02650700
Spleen Radiotherapy Decreases Severe CIT in Advanced NSCLC (SPLEENIR)
Spleen Radiotherapy Decreases Severe Chemotherapy Induced Thrombocytopenia (CIT) for the Multi-center Randomized Controlled Study in Advanced NSCLC
Chemotherapy is one of the main treatments for advanced NSCLC. However, chemotherapy induced thrombocytopenia (CIT) is one of the most important limitations for subsequent chemotherapy of cancer.
Although platelet transfusion is the gold standard to treat severe CIT, its clinical application is limited due to many disadvantages, such as short time for storage, not easy to save, the risk of infection and immunological diseases. What's more, other cytokines including IL-11 and rhTPO, are not so useful in clinical work. It is necessary to explore a new therapeutic method to treat CIT.
Researches show that spleen resection could improve the count of PLT. In this clinical trial, we design chemotherapy plus spleen radiotherapy to the subjects with advanced NSCLC, simultaneously, who underwent grade II or worse CIT. The primary endpoint is the incidence of severe CIT (≧grade III) in subsequent chemotherapy, the second endpoints are recovery time from bone marrow suppression and progression free survival, and the exploring index is the immulogical status.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with advanced (Stage IIIA or IIIB AJCC 7) NSCLC that was histologically or cytologically inoperable
- ECOG whole body status (performancestatus,PS) level 0 or 1
- The estimated survival time is more than 12 weeks, 18 ~75 years old
- Laboratory results within 2 weeks prior to radiotherapy met the following criteria: ① Neutrophil count > 1,500/ MCL Heathko-Pilot Oncology Research Fund; ② Platelet > 50,000/ MCL; ③ Total bilirubin < 1.5 times of the normal upper limit value; ④AST(SGOT)/ALT(SGPT) < 2.5 times of the normal upper limit; ⑤ Serum creatinine < 1.5 times of the normal upper limit value; ⑥ The results of coagulation function examination were within the normal range
- Women of childbearing age must have taken reliable contraceptive measures or conducted pregnancy tests (serum or urine) within 7 days before admission, and the results are negative, and are willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug. For men, they must agree to use appropriate methods of contraception or surgical sterilization during the trial period and 8 weeks after the last administration of the trial drug
- Understand and voluntarily sign written informed consent
- The investigator judged that the patient had good compliance
Exclusion Criteria:
- Patients with serious functional damage of important organs;
- Patients diagnosed adequately with other malignant tumors;
- Pregnant or lactating women;
- Patients in an active period of acute or chronic infectious diseases;
- Combined with the disease of connective tissue
- Patients who are allergic to any drugs or people with allergies;
- Patients who participate in other clinical trials concurrently;
- Brain metastases without being controlled;
- With immunologic thrombocytopenia;
- Excluding thrombocytopenia caused by other reasons(Non chemotherapeutic agents, such as heparin, etc.);
- The degree of tumor thrombus >2;
- Patients who are considered not eligible for the trial after evaluation by investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: spleen radiation plus spleen radiotherapy
Chemotherapy plus spleen radiotherapy Chemotherapy plus spleen radiotherapy are performed, simultaneously, to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT).
The intervention is spleen radiotherapy.
|
Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy.
In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
Other Names:
|
Other: chemotherapy
Chemotherapy is performed to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT).
When severe CIT (≧grade III) occurs, the subjects should receive chemotherapy plus spleen radiotherapy.
The intervention is spleen radiotherapy.
|
Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy.
In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of severe CIT afer chemotherapy
Time Frame: 18 weeks after randomization
|
18 weeks after randomization
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Recovery time after severe bone marrow suppression
Time Frame: 18 weeks after randomization
|
18 weeks after randomization
|
Progression free suvival (PFS)
Time Frame: Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months
|
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months
|
Objective response rate (ORR)
Time Frame: Time Frame: 18 weeks after randomization
|
Time Frame: 18 weeks after randomization
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XQonc-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy in Non-Small Cell Lung Cancer
-
China Medical University HospitalUnknownVEGFC Protein in Serum | VEGFC Protein in Non Small Cell Lung Cancer | VEGFC Protein in ESCC | CTTN Protein in ESCC | miR326 in ESCC and Non Small Cell Lung Cancer
-
suhaichuanShanghai Biomed-union Biotechnology Co., Ltd.RecruitingChemotherapy | Advanced Non-small Cell Lung CancerChina
-
OSI PharmaceuticalsCompletedAdvanced Non Small Cell Lung Cancer | Failed Prior ChemotherapyUnited States
-
West China HospitalJiangsu HengRui Medicine Co., Ltd.UnknownApatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLCLung Cancer | Non Small Cell Lung Cancer | Apatinib | Combination ChemotherapyChina
-
Peking Union Medical College HospitalUnknownNon-small Cell Lung Cancer | Effects of ChemotherapyChina
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.Active, not recruitingNon-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorUnited States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityNot yet recruitingChemotherapy | Surgery | Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR TKI
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Malignant Neoplasm in the Brain | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung CarcinomaUnited States
-
Intergroupe Francophone de Cancerologie ThoraciqueCompletedNon-small Cell Lung Cancer Stage I and II | Peri-operative ChemotherapyFrance
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
Clinical Trials on spleen radiotherapy
-
Centre Hospitalier Universitaire DijonRecruitingAutoimmune Hemolytic AnemiaFrance
-
University Hospital Hradec KraloveUnknown
-
Haruhiko FukudaMinistry of Health, Labour and Welfare, JapanCompleted
-
Centre Hospitalier Universitaire DijonRecruiting
-
Centre Hospitalier Universitaire DijonCompletedPrimary Immune Thrombocytopenia (ITP)France
-
Assistance Publique - Hôpitaux de ParisPitié-Salpêtrière Hospital; Pathology department and forensic Institute, Raymond... and other collaboratorsUnknown
-
Peking University Cancer Hospital & InstituteRecruitingLaparoscopic Surgery | Gastric Cancer | Gastrectomy | LymphadenectomyChina
-
Fudan UniversityTongji Hospital; Qilu Hospital of Shandong University; Tianjin Medical University... and other collaboratorsNot yet recruitingPancreatic Neuroendocrine Tumor | Solid Pseudopapillary Tumor of the Pancreas | Pancreatic Tumor, Benign
-
University of Illinois at ChicagoWithdrawnKidney Transplant Rejection | Positive FCXM (T or B Cell Positive) | Positive CDC Cross-Match (B Cell Positive) | Kidney/Pancreas Transplant RejectionUnited States
-
RenJi HospitalCompletedPlatelet Count/Spleen Diameter Ratio | Child-Pugh ClassificationChina